Veglio F, Schiavone D, Rossi A, Chiandussi L
Dipartimento di Medicina e Oncologia Sperimentale, University of Turin, Italy.
Riv Eur Sci Med Farmacol. 1994 May-Aug;16(3-4):85-90.
The acute effects of doxazosin, a new selective alpha-1 adrenergic blocking agent, on blood pressure, heart rate, and on some circulating vasoactive hormones, such as plasma renin activity, catecholamines, serotonin and endothelin-1 in ten healthy normotensive volunteers and eight moderate-severe essential hypertensives were studied. Two milligrams doxazosin was administered orally in randomised fashion as compared to placebo and the acute effects were evaluated one half to four hours later. Doxazosin did not reduce blood pressure and did not increase heart rate in normotensive subjects as compared to placebo. A significant decrease in blood pressure was found in hypertensives after doxazosin (p < 0.01), without change in heart rate. Simultaneously, doxazosin did not modify plasma renin activity, catecholamines, serotonin and endothelin-1 concentrations both in normotensive and hypertensive subjects when compared with placebo administration. Thus, it appears that doxazosin does not influence local and systemic vasopressor hormones involving in the regulation of blood pressure. In conclusion, the lack of effects on plasma vasoactive factors confirms the selective alpha-1 postsynaptic antagonism of doxazosin and an effective antihypertensive action in the treatment of essential hypertension.
研究了新型选择性α-1肾上腺素能阻滞剂多沙唑嗪对10名健康血压正常志愿者和8名中度至重度原发性高血压患者的血压、心率以及一些循环血管活性激素（如血浆肾素活性、儿茶酚胺、血清素和内皮素-1）的急性影响。与安慰剂相比，以随机方式口服2毫克多沙唑嗪，并在半小时至四小时后评估急性影响。与安慰剂相比，多沙唑嗪在血压正常的受试者中未降低血压且未增加心率。多沙唑嗪治疗后高血压患者的血压显著降低（p < 0.01），心率无变化。同时，与给予安慰剂相比，多沙唑嗪在血压正常和高血压患者中均未改变血浆肾素活性、儿茶酚胺、血清素和内皮素-1的浓度。因此，多沙唑嗪似乎不影响参与血压调节的局部和全身血管加压激素。总之，对血浆血管活性因子缺乏影响证实了多沙唑嗪的选择性α-1突触后拮抗作用以及在原发性高血压治疗中的有效降压作用。
